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COMMENTARY
Sartans for hypertension – implications of the Valsartan
Antihypertensive Long-term Use Evaluation (VALUE) trial
Angiotensin receptor blockers (ARBs), also known as
sartans, block the activation of angiotensin type 1 receptors
and have a recognised role in the treatment of heart failure
and nephropathy. The Losartan Intervention For Endpoint
reduction in hypertension (LIFE) study1 and the Study on
Cognition and Prognosis in the Elderly (SCOPE)2 were two
large clinical trials of ARBs in the treatment of hypertension.
The LIFE study showed that a losartan-based regimen
was superior to an atenolol-based regimen in preventing car-
diovascular events (mainly strokes) in hypertensive patients
with electrographic left ventricular hypertrophy. The favour-
able results in LIFE study have led to claims that ARBs are
especially beneficial in patients with left ventricular hyper-
trophy and especially good at preventing strokes. The
SCOPE study randomised elderly hypertensive patients into
two groups: one group was given candesartan and the other,
a placebo.2 Additional medications were allowed for blood
pressure control, so the difference in blood pressure in the
two randomised groups was minimal. Unlike the LIFE study,
the SCOPE study showed no statistically significant differ-
ences in the main endpoints in the two groups. Thus, the
results of the Valsartan Antihypertensive Long-term Use
Evaluation (VALUE) trial—in which valsartan was com-
pared with amlodipine, a calcium channel blocker—were
eagerly anticipated. A positive result would propel ARBs to
become the preferred treatment for hypertension.
The results of VALUE have just been announced at the
14th European Meeting on Hypertension in Paris and
published.3 In terms of the primary composite endpoint,
there was no significant difference between the treatments.
In fact, when comparing the two groups, the patients treated
with valsartan suffered more cases of myocardial infarction
and stroke (P=0.02 and P=0.08, respectively), instead of
receiving greater protection from those diseases. On the plus
side, there were fewer cases of new-onset diabetes in the
valsartan-treated group than in the amlodipine-treated group
(13.1% versus 16.4%, P<0.0001).
The findings in VALUE do not support claims that ARBs
are particularly good for the heart or the brain. Instead, they
emphasise the importance of good blood pressure control.
In the valsartan-treated group, the average blood pressure
was about 2.0 mm Hg/1.6 mm Hg higher in the valsartan-
treated group over the course of the trial. The difference
was even greater in the first 6 months. The investigators
attributed the negative results of the study to this blood
pressure difference and devised a new statistical test called
serial median matching to support their interpretation.
Ironically, a similar mismatch of blood pressure in the treat-
ment groups in the LIFE study1 and the Heart Outcomes
Prevention Evaluation (HOPE) study4 had not undermined
the positive interpretation of these studies. Favourable
results in large clinical trials comparing antihypertensive
drugs increasingly depend on small and inconspicuous blood
pressure differences.
It now seems clearer than ever that meticulous control
of blood pressure is important and worthwhile. A good
antihypertensive agent must at least do that. Hypertension
affects about 20% of the general population and more
than half of the elderly.5 Unfortunately, just over half
of the hypertensive patients are on treatment, and good
control is achieved in fewer than half of those being
treated.6 The priority must surely be the detection of hyper-
tension and other risk factors in the community, and
achieving good blood pressure control. For the majority of
hypertensive patients, good control requires the use of
more than one class of antihypertensive drugs. Angiotensin
receptor blockers are well tolerated and may reduce new-
onset diabetes, whilst calcium channel blockers lower blood
pressure highly effectively in the Chinese. Both have a place
in the formulary. Debating which antihypertensive drug is
the best is only of commercial, and not academic, interest.
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